Bio-Rad Laboratories ((BIO)) has held its Q3 earnings call. Read on for the main highlights of the call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bio-Rad Laboratories’ recent earnings call painted a picture of resilience amidst challenges. The company demonstrated strength in areas like process chromatography and droplet digital PCR strategy, despite facing headwinds in the Life Science segment and experiencing a decline in gross margins. The decision to maintain full-year guidance reflects a sense of cautious optimism from Bio-Rad’s leadership.
Strong Performance in Process Chromatography
Process chromatography was a standout performer for Bio-Rad, achieving strong double-digit growth year-over-year. This growth was attributed to the timing of customer orders within the quarter, highlighting the segment’s robust demand and strategic importance to the company’s portfolio.
Progress in Droplet Digital PCR Strategy
Bio-Rad made significant strides in its Droplet Digital PCR strategy, with advancements including global sales training on new QX platforms and expanded partnerships with Gencurix and Biodesix. These efforts underscore the company’s commitment to innovation and market expansion in this area.
Increase in Non-GAAP Operating Margin
The company reported an increase in its non-GAAP operating margin to 11.8% in Q3 2025, up from 11.3% in the same quarter of the previous year. This improvement reflects Bio-Rad’s proactive cost management strategies, which have helped mitigate some financial pressures.
Maintained Full Year Guidance
Despite the challenges faced, Bio-Rad maintained its 2025 full-year outlook, expecting currency-neutral revenue growth to range from flat to 1%. This decision indicates confidence in the company’s strategic direction and operational resilience.
Softness in Life Science Segment
The Life Science segment experienced a 6% year-over-year revenue decline, exacerbated by ongoing softness in academic research and biotech end markets. This segment’s performance remains a concern, highlighting the need for strategic adjustments.
Gross Margin Decline
Bio-Rad’s Q3 2025 GAAP gross margin fell to 52.6%, down from 54.8% in Q3 2024. The decline was driven by higher material costs and reduced fixed manufacturing absorption, presenting a challenge for the company’s profitability.
Challenges in China
Sales of Clinical Diagnostics in China decreased by 1.8% on a currency-neutral basis, primarily due to lower reimbursement rates for diabetes testing. This highlights the external pressures faced in international markets, particularly in China.
Decrease in Free Cash Flow
Free cash flow for Q3 2025 was $89 million, a decrease from $123 million in Q3 2024. This decline reflects the financial challenges and operational adjustments the company is navigating.
Currency-Neutral Revenue Decline
On a currency-neutral basis, Bio-Rad’s Q3 2025 net sales represented a 1.7% year-over-year decrease, underscoring the impact of currency fluctuations on the company’s financial performance.
Forward-Looking Guidance
Bio-Rad’s forward-looking guidance remains steady, with expectations for currency-neutral revenue growth between flat and 1% for 2025. The company projects non-GAAP gross and operating margins to be between 53.5% to 54.5% and 12% to 13%, respectively. These projections reflect a balanced approach to navigating current market conditions while positioning for future growth.
In conclusion, Bio-Rad Laboratories’ earnings call highlighted a company that is navigating a complex landscape with both challenges and opportunities. While certain segments face headwinds, the company’s strategic initiatives in process chromatography and digital PCR, along with disciplined cost management, provide a foundation for cautious optimism. Investors and stakeholders will be watching closely as Bio-Rad continues to execute its strategies in the coming quarters.